15-keto-13-14-dihydroprostaglandin-f2alpha and flunixin-meglumine

Flunixin meglumine (FM) was administered either orally as granules or intravenously to six heifers in a two period crossover study. Single doses of 2.2 mg/kg body weight were used. Pharmacokinetic variables were calculated using statistical moment methods. The effect exerted by flunixin was measured as changes in the basal plasma concentration of the main metabolite of prostaglandin (PG) F2 alpha. After oral FM the arithmetic means of pharmacokinetic variables were: MRT = 12.7 h; MAT = 6.3 h; Cmax = 0.9 microgram/mL; tmax = 3.5 h. The bioavailability was 60% and the mean half-life (harmonic mean) was 6.2 h. Oral administration of FM inhibited as effectively as intravenous administration the prostaglandin biosynthesis. The concentration of the PG metabolite decreased almost as rapidly as after intravenous administration. The duration of the effect was prolonged and the PG metabolite concentration was significantly lower between 10 and 30 h after oral than after intravenous administration. The results indicate that oral dosing of flunixin, in the form of granules, can be an alternative to intravenous administration for therapeutic use in cattle.

Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Cattle; Chromatography, High Pressure Liquid; Clonixin; Cross-Over Studies; Dinoprost; Estrus; Female; Half-Life; Injections, Intravenous

The objective was to determine differences in follicle and reproductive hormone characteristics in mares with ovulatory and flunixin meglumine (FM)-induced anovulatory cycles. Estrous mares were given 1500 IU hCG when the follicle was ≥ 32 mm (0 h). In Experiment 1, control mares (n = 7) were not treated further. The remaining mares (n = 11) were given 1.7 mg/kg FM i.v. twice daily, from 0 to 36 h after hCG treatment. Blood samples and ultrasonographic examinations were performed every 12 h. All control mares ovulated normally between 36 and 48 h. In contrast, eight of 11 FM mares did not ovulate, but developed luteinized unruptured follicles (LUFs). Three FM-treated mares did not develop conventional LUFs. Plasma progesterone concentrations were lower (P < 0.05) in LUF mares at 96, 120, and 216 h than in controls, whereas plasma LH concentrations were higher (P < 0.05) between 108 and 120 h in LUF mares than in controls. Plasma concentrations of PGFM and estradiol did not differ significantly between groups. In Experiment 2, the three mares that did not develop LUFs were treated, during the consecutive cycle, with the same dose of FM but with increased frequency at zero, 12, 24, 30, 36, and 48 h after hCG. One mare formed a LUF, whereas the other two did not. These two mares had lower LH concentrations than LUF or control mares in the two consecutive cycles. In conclusion, systemic treatment with FM blocked ovulation in 73% of treated mares. Mares with LUFs had lower progesterone and higher LH concentrations than control mares.

Topics: Animals; Anovulation; Chorionic Gonadotropin; Clonixin; Dinoprost; Estradiol; Female; Hormones; Horses; Luteinization; Luteinizing Hormone; Ovarian Follicle; Ovulation; Progesterone; Prostaglandin Antagonists; Ultrasonography

Flunixin meglumine (FM; 2.5 mg/kg) was given to heifers at three 8-h intervals, 16 d after ovulation (first treatment = Hour 0) to inhibit the synthesis of prostaglandin F(2α) (PGF), based on plasma concentrations of a PGF metabolite (PGFM). Blood samples were collected at 8-h intervals from 15 to 18 d in a vehicle (control) and FM group (n = 16/group). Hourly samples were collected from Hours -2 to 28 in 10 heifers in each group. Heifers that were in preluteolysis or luteolysis at Hour 0 based on plasma progesterone (P4) concentrations at 8-h intervals were partitioned into subgroups. Concentration of PGFM was reduced (P < 0.05) by FM treatment in each subgroup. For the preluteolytic subgroup, the first decrease (P < 0.05) in P4 concentration after Hour 0 occurred at Hours 24 and 40 in the vehicle and FM groups, respectively. Plasma P4 concentrations 32 and 40 h after the beginning of luteolysis in the luteolytic subgroup were greater (P < 0.05) in the FM group. Concentration at the peak of a PGFM pulse in the FM group was greater (P < 0.05) in the luteolytic than in the preluteolytic subgroup. The peak of a PGFM pulse occurred more frequently (P < 0.001) at the same hour as the peak of an LH fluctuation than at the ending nadir of an LH fluctuation. In conclusion, a reduction in prominence of PGFM pulses during luteolysis delayed completion of luteolysis, and treatment with FM inhibited PGFM production more during preluteolysis than during luteolysis.

Topics: Animals; Cattle; Chi-Square Distribution; Clonixin; Dinoprost; Female; Luteinizing Hormone; Luteolysis; Progesterone; Prostaglandin Antagonists; Random Allocation

The aim of this study was to determine the effects of enrofloxacin (ENR), flunixin meglumine (FM) and dexamethasone (DEX) on antioxidant status and organ damage markers in experimentally-induced endotoxemia. Rats were divided into three groups. To induce endotoxemia, lipopolysaccharide (LPS) was injected into all groups, including the positive control. The two other groups received the following drugs (simultaneously with LPS): ENR + FM + low-dose DEX and ENR + FM + high-dose DEX. After the treatments, blood samples were collected at 0, 1, 2, 4, 6, 8, 12, 24 and 48 h. Oxidative stress parameters were determined by ELISA, while serum organ damage markers were measured by autoanalyser. LSP increased (p < 0.05) malondialdehyde, 13,14-dihydro-15-keto-prostaglandin F(2 alpha) and nitric oxide, while LPS reduced vitamin C. These changes were especially inhibited (p < 0.05) by ENR + FM + high-dose DEX. LPS increased organ damages markers. Cardiac and hepatic damage was not completely inhibited by any treatment, whereas renal damage was inhibited by two treatments. This study suggested that ENR + FM + high-dose DEX is most effective in the LPS-caused oxidative stress and organ damages.

Topics: Animals; Ascorbic Acid; Autoanalysis; Biomarkers; Clonixin; Dexamethasone; Dinoprost; Disease Models, Animal; Drug Therapy, Combination; Enrofloxacin; Enzyme-Linked Immunosorbent Assay; Female; Fluoroquinolones; Heart Diseases; Kidney Diseases; Lipopolysaccharides; Liver Diseases; Male; Malondialdehyde; Multiple Organ Failure; Nitric Oxide; Oxidative Stress; Rats; Rats, Sprague-Dawley; Shock, Septic; Superoxide Dismutase; Time Factors

This study was undertaken to determine whether induction of ovarian oxytocin after oestradiol treatment on day 15 after oestrus is mediated through prostaglandin secretion by blocking prostaglandin synthesis using finadyne, an inhibitor of the cyclo-oxygenase pathway. Nine ewes with ovarian autotransplants were assigned randomly to receive an i.m. injection of either oestradiol benzoate (50 microg) in peanut oil ( n= 5) or oestradiol benzoate plus finadyne (2.2 mg kg (-1)) ( n= 4) at 3 h intervals starting at the time of oestradiol injection. Blood samples were collected from the ovarian and contralateral jugular veins at 30 min intervals for 6 h before and at 15 min intervals for up to 9 h after the oestradiol and finadyne injections. The secretion rate of ovarian progesterone remained high in all ewes, thus indicating the presence of a functional corpus luteum. Peripheral oestradiol concentrations were significantly (P < 0.001) higher during the 9 h after oestradiol injection in both groups. None of the oestradiol-finadyne-treated ewes showed significant pulses in either ovarian oxytocin secretion or release of the prostaglandin F(2alpha) metabolite 13,14-dihydro-15-keto PGF(2alpha) (PGFM) after injections. In ewes treated with oestradiol only, at least one detectable pulse of ovarian oxytocin and jugular PGFM was observed with mean +/- SEM amplitude of 17.7 +/- 7.29 ng min (-1) and 237.18 +/- 43.13 pg ml (-1), respectively. The areas under the curve for ovarian oxytocin and jugular PGFM pulses were significantly increased after oestradiol treatment. These findings demonstrate that initiation of the arachidonic acid cascade is important for the secretion of oxytocin after oestrogen treatment.

Topics: Animals; Clonixin; Corpus Luteum; Cyclooxygenase Inhibitors; Dinoprost; Estradiol; Estrus; Female; Ovary; Oxytocin; Progesterone; Sheep; Transplantation, Autologous; Uterus

The secretory patterns of progesterone in relation to concentrations of 15-ketodihydro-PGF(2alpha) (PGFM) during the period of luteolysis or of maternal recognition of pregnancy were determined in the blood of llamas mated either with an intact or a vasectomized male. The ability of flunixin meglumine (FM) to postpone luteolysis in non-pregnant llamas was investigated by injecting the drug intravenously every 6 h at a dose of 2.2 mg/kg from days 6 to 12 post-copulation into a group of non-pregnant llamas. A pulsatile pattern of prostaglandin release was recorded during luteolysis in non-pregnant llamas, giving further support to the hypothesis that PGF(2alpha) is the luteolytic agent in llamas. The mean number of peaks per animal rose from 0.3 on day 7 to 3.8 on day 10 and then declined to 1.1 on day 12 with corresponding mean peak amplitude changing from 465 to 1234 and 566 pmol l(-1), respectively. In pregnant llamas, prostaglandin pulsatile release also occurred. The mean number of peaks per animal rose from 0.4 on day 7 to 0.8 on day 10 and then declined to 0.2 on day 11 and 0.6 on day 12, with corresponding mean peak amplitude changing from 494 to 676, 388 and 547 pmol l(-1), respectively. The transient decrease and subsequent recovery in progesterone concentrations was observed to occur in connection with prostaglandin release during early pregnancy. Oestradiol-17beta plasma peak concentrations attained after luteolysis were significantly higher than those recorded in early pregnant animals (around 30 pmol l(-1) and ll pmol l(-1)). Concentrations of PGFM decreased rapidly after the first administration of FM and remained low throughout the first 2 days of treatment. Thereafter, pulsatile release of prostaglandins started, and luteolysis proceeded; but a delay of 1-1.5 days in the progesterone decline was observed. Thus, it might be suggested that a higher dose and/or a more intensive injection schedule is required in llamas than in other ruminants to prevent luteolysis.

Topics: Animals; Camelids, New World; Clonixin; Corpus Luteum; Dinoprost; Estradiol; Female; Male; Pregnancy; Progesterone; Prostaglandin Antagonists

At birth, the physiological role of prostaglandins in bitches is unclear. Bitches were treated before parturition with either saline, the prostaglandin analogue, sodium cloprostenol, or the prostaglandin synthetase inhibitor, flunixin meglumine. The animals were examined regularly to determine the onset of parturition and a series of blood samples were taken to define the hormonal profiles before, during and after birth. Animals treated with cloprostenol whelped earlier than did controls. In addition, the prostaglandin F2 alpha metabolite surge and decrease in plasma progesterone concentration and rectal temperature were earlier than in controls. Flunixin meglumine disrupted the normal 13,14-dihydro-15-keto prostaglandin F2 alpha profile but did not abolish prostaglandin synthesis completely or delay the onset of labour in treated animals. This study confirms that prostaglandins induce luteolysis and the onset of labour in the bitch. However, the partial inhibition of prostaglandin synthesis does not prevent parturition.

Topics: Analysis of Variance; Animals; Area Under Curve; Birth Weight; Body Temperature; Clonixin; Cloprostenol; Cyclooxygenase Inhibitors; Dinoprost; Dogs; Drinking; Female; Labor Onset; Luteolysis; Pregnancy; Progesterone; Prostaglandins, Synthetic

Flunixin meglumine (FM), an inhibitor of the cyclo-oxygenase pathway of the prostaglandin synthesis, was used to evaluate the andrological changes following an endotoxin (ET) administration in the boar. FM was injected as a single dose 10 min prior to an ET injection. Blood plasma was analysed for the contents of 15-ketodihydroprostaglandin (PG) F2 alpha LH, testosterone and cortisol. Twelve h after the ET administration, the boars were castrated and the testes examined by light and electron microscopy. The results were compared between controls, ET-, FM- and FM+ET-treated boars. An increase in 15-ketodihydro-PGF2 alpha levels was seen following ET administration. Pretreatment with FM decreased the levels of 15-ketodihydro-PGF2 alpha during 2 h. Following the ET administration a voluminous increase in testosterone levels as well as changed LH levels were seen. Similar alterations in hormonal levels were observed also after pretreatment with FM, however, delayed about 2 h, and during this time a marked decrease in testosterone levels was seen. In the testes an infiltration of polymorphonuclear neutrophils (PMN) in the interstitium and histological changes among the Leydig cells were seen after ET injection. Pretreatment with FM reduced the number of invading PMN and the Leydig cells appeared less affected. The results show that FM modulated the negative effects of ET on the testicular function in the boar, indicating that the initiation of the arachidonic acid cascade was of importance for the induction of the alterations following an ET injection.

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bacterial Toxins; Clonixin; Dinoprost; Endotoxins; Male; Salmonella; Swine; Testis

In the present study the effect of Flunixin meglumine (FM), a cyclooxygenase inhibitor, was investigated on postpartal prostaglandin production and uterine activity in the cow. For that purpose 8 cows were given FM in a dose of 2.2 mg/Kg b.w. twice daily (08.00 and 16.00 h) for the first 10 days p.p. Blood samples were collected at various times before, during and after parturition and the concentrations of 15-keto-13,14-dihydro-PGF2 alpha (PGFM), progesterone as well as adrenaline and noradrenaline determined. Eight cows served as controls. Uterine activity was measured by means of pressure microsensors and electrodes which were surgically implanted into the uterine wall before parturition. During the whole treatment period FM inhibited endogenous PG-production by more than 80% (p < 0.05). The suppressive effect of FM was maximal 4 h after the last injection and lasted no longer than 8 h. PGF2 alpha-suppression clearly decreased spontaneous uterine motility and reduced the myometrial response to ocytocin (5 IU i.v.) and PGF2 alpha (15 mg i.v.). Treatment with FM did not interfere with uterine involution, the return to cyclicity and the first postpartal cycle length. Also, no obvious effects were seen on catecholamine concentrations which fluctuated during parturition without regularly representing the actual stress situation. Our results demonstrate that FM is able to effectively inhibit PGF2 alpha-secretion as well as uterine activity in the cow. Further evaluation of FM as a tocolyticum or in the treatment of uterine infections is required.

Topics: Animals; Catecholamines; Cattle; Clonixin; Dinoprost; Female; Labor, Obstetric; Postpartum Period; Pregnancy; Pregnancy, Animal; Uterus

Three gilts were each equipped with 2 ultra-miniature pressure sensors, placed at 2 different points along the same isthmus of the oviduct. Following base recordings of isthmic intraluminal pressure, the gilts were treated with 2.2 mg flunixin meglumine (FM) per kg body weight. After FM treatment, the peripheral plasma levels of 15-ketodihydro-PGF2 alpha, the major metabolite of prostaglandin F2 alpha (PGF2 alpha), decreased within 30 min. The frequency of the phasic pressure fluctuations in the isthmus of the oviduct decreased after FM treatment. Exogenous administration of PGF2 alpha increased the peripheral plasma levels of 15-ketodihydro-PGF2 alpha. When administered at a dose of 0.1 mg, PGF2 alpha produced an increase in the frequency of the phasic pressure fluctuations in the oviductal isthmus. When the PGF2 alpha dose was increased to 0.5 mg, a marked increase in the base and total pressures was seen in addition to the increase in the frequency of the phasic pressure fluctuations.

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Clonixin; Dinoprost; Estrus; Fallopian Tubes; Female; Male; Pressure; Swine

The aim of this study was to determine the effect of flunixin meglumine (FM), a substance which inhibits the prostaglandin biosynthesis, on the uterine involution. One of the characteristics of the postpartum period in cattle is the massive and extended release of prostaglandin (PG) F2 alpha. Eleven primiparous cows, divided into three groups, were included in the study. The first group was injected with FM four times daily, the second group twice daily and the third group acted as controls. The dose was 2.2 mg/kg body weight injected intramuscularly. The treatment period was 14 days beginning at parturition. Blood samples were collected prior to calving and up to 28 days postpartum. The plasma concentrations of the main circulating PGF2 alpha metabolite, i.e. 15-keto-dihydro-PGF2 alpha, and progesterone were analysed. The involution of the uterus was assessed by rectal palpation and ultrasonography. The study showed that it was not possible to affect the time period to completed uterine involution, not even when a very intensive drug dosage was used. A statistical difference was found between the group receiving the most intensive treatment and the controls, when the areas under the prostaglandin metabolite curve (AUC) were compared. The PG synthesis and release were decreased by the treatment, but never totally suppressed. Even though the treatment with FM did not shorten the time to completed uterine involution, it was not detrimental for the process of involution. However, as the uterine involution is an inflammatory process, flunixin could, as an anti-inflammatory drug, be beneficial under certain circumstances.

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cattle; Clonixin; Dinoprost; Female; Postpartum Period; Progesterone; Uterus

Topics: Animals; Clonixin; Corpus Luteum; Dinoprost; Estrus; Female; Progesterone; Swine

Flunixin meglumine (FM) was injected in 2 oophorectomized cows to follow changes in basal levels of the main circulating prostaglandin (PG)F2 alpha metabolite, 15-ketodihydro-PGF2 alpha. A rapid decrease in the levels was seen after FM and the effect was lasting for about 6 h. Thus, to obtain a full effect of the drug on prostaglandin synthesis it is recommended that FM should be injected 4 times daily. This concept was further studied in 3 cycling heifers which obtained FM 4 times daily from day 15 of the estrous cycle for 7 days (totally 28 injections). During the period of drug administration, prostaglandin metabolite levels were decreased and the expected pulsatile release seen during luteolysis was delayed. The pulsatile release started about one day after cessation of treatment and then luteolysis occurred. Progesterone levels were normal during the FM treatment and dropped concomitantly with the pulsatile release of PGF2 alpha. The levels of progesterone decreased to low levels before the heifers showed signs of estrus and ovulated. The administration of FM causes a situation resembling that seen during early pregnancy and FM can be a useful tool in understanding the mechanism behind maternal recognition of pregnancy.

Topics: Animals; Cattle; Clonixin; Dinoprost; Estrus; Female; Nicotinic Acids; Progesterone; Prostaglandins

The aim of this study was to examine the endocrinological response (15-ketodihydro-PGF2 alpha, progesterone and oestrone sulphate) of pregnant ewes which were constantly treated with flunixin meglumine (FM) after infection with Toxoplasma gondii. Seven Swedish Peltsheep ewes were dosed orally with 2,000 T. gondii oocysts at 90.5 (82-94) days of pregnancy. The ewes were treated with FM, 1 mg/kg, intramuscularly twice a day, starting one day before infection until the end of the gestation period. Further three ewes were treated with FM alone during the corresponding time of pregnancy. Another four ewes were used as uninfected and untreated controls. All infected ewes developed antibodies to T. gondii and aborted, but the FM treated control group and the non-treated control group, which remained seronegative, delivered the lambs in the normal gestation range. No early abortions (less than 10 days after infection) were seen in the infected group. The endocrinological changes reflected the pathological changes in the uterus and foetuses. FM could neither completely inhibit prostaglandin release during abortion nor the physiological change of the hormone before parturition even though it depressed prostaglandin release before abortion or parturition and eliminated fever. The infectious process caused by the organism was probably not affected. FM treatment alone had no observed negative effects on pregnant ewes and their foetuses.

Topics: Animals; Clonixin; Dinoprost; Estrone; Female; Nicotinic Acids; Pregnancy; Progesterone; Sheep; Sheep Diseases; Toxoplasmosis, Animal; Ultrasonography

The effect of flunixin meglumine on prostaglandin synthesis and metabolism was evaluated in the pig in vivo. It was found that the prostaglandin metabolite, 15-ketodihydro-PGF2 alpha, was decreased in the peripheral circulation within 20 min of injection of the drug. In therapeutic doses in the pig the drug had no effect on the metabolism of PGF2 alpha. Flunixin was compared with some other non-steroidal anti-inflammatory drugs in an in vitro test system utilizing sheep vesicular gland microsomes. It was concluded that this drug is a potent inhibitor of prostaglandin synthesis.

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clonixin; Cyclooxygenase Inhibitors; Dinoprost; Estrus; Female; Indomethacin; Male; Mefenamic Acid; Nicotinic Acids; Swine

Feral does of various ages were treated with intravaginal progestagen sponges for 16 days to synchronize oestrus. On Day 2 before sponge removal the goats were given 1200 i.u. PMSG to induce superovulation: 6 of the goats were also injected every 12 h with flunixin meglumine, a prostaglandin (PG) synthetase inhibitor, from Day 3 to 7 of the synchronized oestrous cycle. Jugular blood samples were collected from all females into heparinized syringes at daily intervals over the 2 days before sponge removal, twice daily for the next 2 days, then at hourly intervals from 09:00 to 17:00 h for 2 days and then twice daily for a further 2 days, for measurement of plasma progesterone and the PGF metabolite 13,14-dihydro-15-keto-PGF (PGFM) by radioimmunoassay. Intermittent surges in plasma PGFM concentrations were observed in hourly samples collected from 4/4 untreated females but in only 2/6 of the inhibitor-treated females (P less than 0.05), and the peak plasma PGFM concentrations were reduced in these 2 inhibitor-treated goats compared with the control goats. The corpora lutea (CL) of the inhibitor-treated females appeared to be functional as indicated by the plasma progesterone profile and endoscopic examination of CL. In the control females, however, there was evidence of premature regression of CL. These results suggest that the premature release of PGF-2 alpha may be the cause of premature regression of CL in nanny goats induced to superovulate.

Topics: Animals; Clonixin; Dinoprost; Female; Goats; Gonadotropins, Equine; Luteolysis; Ovulation; Progesterone; Superovulation

Arachidonic acid metabolites (AAM) were measured in milk and plasma during the course of acute endotoxin-induced mastitis in 12 lactating cows. Mastitis was induced by intramammary challenge exposure with 10 micrograms of Escherichia coli (026:B6) endotoxin. Endotoxin was injected into the teat cistern via the teat canal of a single randomly selected rear quarter of each cow. Concentrations of prostaglandin (PG) F2 alpha and thromboxane (Tx) B2 in fat-free unextracted milk and of 15-keto-13,14-dihydro-PGF2 alpha in plasma were measured by radioimmunoassay. Total production of AAM in milk was determined by measuring quarter milk production. The AAM were compared in 6 cows administered flunixin meglumine (1.1 mg/kg of body weight) and in 6 cows administered saline solution. Concentrations of TxB2 in milk were significantly (P less than 0.001) increased during the early course of acute mastitis in endotoxin-treated quarters of cows not administered flunixin meglumine. Peak concentrations of TxB2 in milk occurred at 8 hours after endotoxin inoculation. Flunixin meglumine treatment produced significant (P less than 0.05) reductions in milk TxB2 and plasma 15-keto-13,14-dihydro-PGF2 alpha concentrations. Concentrations of PGF2 alpha in milk and total PGF2 alpha and TxB2 production per quarter per milking were not significantly influenced by endotoxin challenge or by flunixin meglumine treatment.

Topics: Animals; Arachidonic Acid; Arachidonic Acids; Cattle; Clonixin; Dinoprost; Endotoxins; Escherichia coli; Female; Mastitis, Bovine; Milk; Nicotinic Acids; Prostaglandins F; Thromboxane B2